GH
VENTE TOTALE: 1 932 titres (~315 796,34 $ US)
- Insiders
- Tariq Musa, Hidalgo Medina Manuel
- Total bought
- —
- Total sold
- $315,796
- Last activity
- 2026-08-17
- Last synced
-
2026-08-23 00:12:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-07
GH presents a structurally distressed balance sheet with negative equity, extreme leverage, and chronic cash burn that severely undermines the liquidity buffer provided by its current ratio.
The first sentence of the analysis written for GH on 2026-08-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 64.5% | 60.8% | 59.7% | 65.2% | 67.1% | |
| Ebit Margin | -42.1% | -58.5% | -84.4% | -144.8% | -102.2% | |
| Ebitda Margin | -38.1% | -52.8% | -76.8% | -136.8% | -96.2% | |
| Operating Profit Margin | -44.5% | -60.0% | -100.1% | -121.1% | -110.0% | |
| Pretax Profit Margin | -42.5% | -58.9% | -84.9% | -145.4% | -102.9% | |
| Continuous Operations Profit Margin | -42.4% | -59.0% | -85.0% | -145.6% | -103.0% | |
| Net Profit Margin | -42.4% | -59.0% | -85.0% | -145.6% | -108.6% | |
| Bottom Line Profit Margin | -42.4% | -59.0% | -85.0% | -145.6% | -108.6% | |
| Current Ratio | 4.843 | 4.677 | 6.542 | 6.167 | 5.723 | |
| Quick Ratio | 4.559 | 4.362 | 6.241 | 5.900 | 5.565 | |
| Solvency Ratio | -0.178 | -0.242 | -0.268 | -0.399 | -0.246 | |
| Cash Ratio | 1.249 | 2.330 | 5.505 | 0.733 | 2.528 | |
| Price To Earnings Ratio | -30.765 | -8.581 | -6.320 | -4.243 | -25.005 | |
| Price To Earnings Growth Ratio | 4.563 | 0.510 | 0.190 | -0.070 | -0.430 | |
| Forward Price To Earnings Growth Ratio | 4.563 | 0.510 | 0.190 | -0.070 | -0.430 | |
| Price To Earnings Diluted Ratio | -30.765 | -8.581 | -6.320 | -4.243 | -25.005 | |
| Price To Earnings Diluted Growth Ratio | 4.563 | 0.510 | 0.190 | -0.070 | -0.430 | |
| Price To Book Ratio | -128.951 | -26.852 | 19.090 | 46.182 | 15.711 | |
| Price To Sales Ratio | 13.040 | 5.074 | 5.372 | 6.182 | 27.120 | |
| Price To Free Cash Flow Ratio | -54.945 | -13.639 | -8.769 | -7.183 | -35.675 | |
| Price To Operating Cash Flow Ratio | -69.310 | -15.634 | -9.322 | -8.981 | -48.481 | |
| Debt To Assets Ratio | 0.849 | 0.899 | 0.758 | 0.850 | 0.623 | |
| Debt To Equity Ratio | -17.221 | -9.567 | 8.531 | 22.753 | 2.130 | |
| Debt To Capital Ratio | 1.062 | 1.117 | 0.895 | 0.958 | 0.680 | |
| Long Term Debt To Capital Ratio | 1.071 | 1.139 | 0.878 | 0.950 | 0.638 | |
| Financial Leverage Ratio | -20.277 | -10.638 | 11.258 | 26.753 | 3.418 | |
| Working Capital Turnover Ratio | 0.986 | 0.750 | 0.527 | 0.469 | 0.273 | |
| Operating Cash Flow Ratio | -0.610 | -1.063 | -1.578 | -1.602 | -1.074 | |
| Operating Cash Flow Sales Ratio | -0.188 | -0.325 | -0.576 | -0.688 | -0.559 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.261 | 1.146 | 1.063 | 1.250 | 1.359 | |
| Debt Service Coverage Ratio | -95.623 | -151.649 | -168.344 | -239.057 | -139.667 | |
| Interest Coverage Ratio | -112.201 | -171.869 | -219.055 | -211.245 | -159.488 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.108 | -0.180 | -0.240 | -0.226 | -0.152 | |
| Capital Expenditure Coverage Ratio | -3.825 | -6.836 | -15.863 | -3.995 | -2.786 | |
| Dividend Paid And Capex Coverage Ratio | -3.825 | -6.836 | -15.863 | -3.995 | -2.786 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -37.811 | -11.690 | -7.499 | -6.516 | -30.629 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 64.5% | ▲3.7% | ▲1.0% |
| Ebit Margin | -42.1% | ▲16.4% | ▲44.3% |
| Ebitda Margin | -38.1% | ▲14.7% | ▲42.1% |
| Operating Profit Margin | -44.5% | ▲15.5% | ▲42.6% |
| Pretax Profit Margin | -42.5% | ▲16.4% | ▲44.4% |
| Continuous Operations Profit Margin | -42.4% | ▲16.7% | ▲44.6% |
| Net Profit Margin | -42.4% | ▲16.7% | ▲45.7% |
| Bottom Line Profit Margin | -42.4% | ▲16.7% | ▲45.7% |
| Current Ratio | 4.843 | ▲0.166 | ▼-0.748 |
| Quick Ratio | 4.559 | ▲0.197 | ▼-0.766 |
| Solvency Ratio | -0.178 | ▲0.064 | ▲0.089 |
| Cash Ratio | 1.249 | ▼-1.080 | ▼-1.220 |
| Price To Earnings Ratio | -30.765 | ▼-22.184 | ▼-15.782 |
| Price To Earnings Growth Ratio | 4.564 | ▲4.053 | ▲3.611 |
| Forward Price To Earnings Growth Ratio | 4.564 | ▲4.053 | ▲3.611 |
| Price To Earnings Diluted Ratio | -30.765 | ▼-22.184 | ▼-15.782 |
| Price To Earnings Diluted Growth Ratio | 4.564 | ▲4.053 | ▲3.611 |
| Price To Book Ratio | -128.951 | ▼-102.098 | ▼-113.987 |
| Price To Sales Ratio | 13.040 | ▲7.966 | ▲1.683 |
| Price To Free Cash Flow Ratio | -54.944 | ▼-41.306 | ▼-30.903 |
| Price To Operating Cash Flow Ratio | -69.310 | ▼-53.676 | ▼-38.964 |
| Debt To Assets Ratio | 0.849 | ▼-0.050 | ▲0.053 |
| Debt To Equity Ratio | -17.221 | ▼-7.653 | ▼-18.546 |
| Debt To Capital Ratio | 1.062 | ▼-0.055 | ▲0.119 |
| Long Term Debt To Capital Ratio | 1.071 | ▼-0.069 | ▲0.136 |
| Financial Leverage Ratio | -20.277 | ▼-9.639 | ▼-22.380 |
| Working Capital Turnover Ratio | 0.986 | ▲0.235 | ▲0.385 |
| Operating Cash Flow Ratio | -0.610 | ▲0.453 | ▲0.575 |
| Operating Cash Flow Sales Ratio | -0.188 | ▲0.136 | ▲0.279 |
| Free Cash Flow Operating Cash Flow Ratio | 1.262 | ▲0.115 | ▲0.045 |
| Debt Service Coverage Ratio | -95.623 | ▲56.025 | ▲63.245 |
| Interest Coverage Ratio | -112.201 | ▲59.668 | ▲62.571 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.108 | ▲0.071 | ▲0.073 |
| Capital Expenditure Coverage Ratio | -3.825 | ▲3.012 | ▲2.836 |
| Dividend Paid And Capex Coverage Ratio | -3.825 | ▲3.012 | ▲2.836 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -37.811 | ▼-26.121 | ▼-18.982 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $12.81B | $3.75B | $3.03B | $2.78B | $10.13B | |
| Enterprise value | $14.14B | $4.56B | $3.25B | $4.01B | $11.01B | |
| EV / Sales | 14.40x | 6.17x | 5.76x | 8.91x | 29.48x | |
| EV / Op. cash flow | -76.52x | -19.01x | -10.00x | -12.95x | -52.70x | |
| EV / Free cash flow | -60.66x | -16.59x | -9.41x | -10.36x | -38.78x | |
| EV / EBITDA | -37.81x | -11.69x | -7.50x | -6.52x | -30.63x | |
| Net debt / EBITDA | -3.56x | -2.08x | -0.51x | -2.00x | -2.45x | |
| Current ratio | 4.84x | 4.68x | 6.54x | 6.17x | 5.72x | |
| Income quality | 0.44x | 0.55x | 0.68x | 0.47x | 0.54x | |
| Graham net-net | -$6 | -$5 | -$3 | -$4 | -$5 | |
| Tax burden | 99.7% | 100.3% | 100.1% | 100.2% | 105.5% | |
| Interest burden | 100.9% | 100.6% | 100.5% | 100.4% | 100.7% | |
| Working capital | $1.16B | $829.5M | $1.14B | $998.4M | $919.4M | |
| Invested capital | $1.57B | $1.12B | $1.46B | $1.36B | $1.25B | |
| Return on assets | -20.7% | -29.4% | -26.8% | -40.7% | -18.4% | |
| Operating ROA | -25.0% | -27.1% | -33.3% | -28.5% | -18.4% | |
| Return on tangible assets | -21.8% | -29.6% | -27.0% | -41.0% | -18.5% | |
| Return on equity | 419.2% | 312.5% | -302.1% | -1087.7% | -62.9% | |
| Return on invested capital | -25.1% | -34.4% | -35.1% | -37.8% | -20.3% | |
| Return on capital employed | -25.6% | -35.2% | -35.7% | -38.4% | -20.4% | |
| Earnings yield | -3.3% | -11.6% | -15.8% | -23.6% | -4.0% | |
| Free cash flow yield | -1.8% | -7.3% | -11.4% | -13.9% | -2.8% | |
| Capex / Op. cash flow | -26.1% | -14.6% | -6.3% | -25.0% | -35.9% | |
| Capex / Depreciation | 121.6% | 82.8% | 47.8% | 215.4% | 336.9% | |
| Capex / Sales | 4.9% | 4.7% | 3.6% | 17.2% | 20.1% | |
| SG&A / Sales | 71.9% | 73.8% | 80.0% | 103.2% | 106.7% | |
| R&D / Sales | 37.1% | 47.1% | 65.1% | 83.2% | 70.4% | |
| Stock comp / Sales | 16.9% | 19.0% | 16.1% | 21.1% | 40.5% | |
| Intangibles / Total assets | 5.1% | 0.7% | 0.7% | 0.9% | 0.8% | |
| Days sales outstanding | 51d | 54d | 57d | 79d | 95d | |
| Days payables outstanding | 57d | 49d | 83d | 161d | 114d | |
| Operating cycle | 141d | 144d | 157d | 199d | 186d | |
| Cash conversion cycle | 84d | 95d | 74d | 39d | 72d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+241.5%EV / Sales ▲+133.3%EV / EBITDA ▼-223.5%EV / Op. cash flow ▼-57.506Earnings yield ▲+0.084
Profitability
Return on equity ▲+1.067Return on assets ▲+0.087Return on invested capital ▲+0.093Return on capital employed ▲+0.096Operating ROA ▲+0.021Income quality ▼-0.106Tax burden ▼-0.006
Efficiency
Days sales outstanding ▼-3.218Days payables outstanding ▲+8.382Operating cycle ▼-2.935Cash conversion cycle ▼-11.317Capex / Sales ▲+0.002R&D / Sales ▼-0.100
Balance-sheet strength
Current ratio ▲+0.165Net debt / EBITDA ▼-1.485Working capital ▲+333785000.000Invested capital ▲+452599000.000Intangibles / Total assets ▲+0.044
Change over 5 years
Valuation
Market cap ▲+26.4%EV / Sales ▼-51.2%EV / EBITDA ▼-23.4%EV / Op. cash flow ▼-23.820Earnings yield ▲+0.008
Profitability
Return on equity ▲+4.821Return on assets ▼-0.023Return on invested capital ▼-0.048Return on capital employed ▼-0.051Operating ROA ▼-0.066Income quality ▼-0.099Tax burden ▼-0.058
Efficiency
Days sales outstanding ▼-44.155Days payables outstanding ▼-57.443Operating cycle ▼-45.433Cash conversion cycle ▲+12.011Capex / Sales ▼-0.152R&D / Sales ▼-0.334
Balance-sheet strength
Current ratio ▼-0.880Net debt / EBITDA ▼-1.111Working capital ▲+243877000.000Invested capital ▲+320418000.000Intangibles / Total assets ▲+0.043
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-13 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-12-22 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-02 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-10-22 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-10-05 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-05-01 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-04-27 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-02-14 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-14 Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.
- 2026-08-12 Guardant Health, Inc. (GH) Presents at Canaccord Genuity''s 46th Annual Growth Conference Transcript Guardant Health, Inc. (GH) Presents at Canaccord Genuity''s 46th Annual Growth Conference Transcript
- 2026-08-12 Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.
- 2026-08-11 Guardant Health: Screening And MRD Are Just Getting Started Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.
- 2026-08-10 Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant''s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs.
- 2026-08-09 Empowered Funds LLC Trims Stock Position in Guardant Health, Inc. $GH Empowered Funds LLC trimmed its holdings in Guardant Health, Inc. (NASDAQ: GH) by 81.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,457 shares of the company''s stock after selling 58,422 shares during the quarter. Empowered Funds LLC''s holdings in
- 2026-08-08 Dimensional Fund Advisors LP Sells 123,826 Shares of Guardant Health, Inc. $GH Dimensional Fund Advisors LP lowered its position in Guardant Health, Inc. (NASDAQ: GH) by 40.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 182,727 shares of the company''s stock after selling 123,826 shares during the quarter. Dimensional Fund Advisors LP owned about
- 2026-08-06 A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $64.71 vs Price $157.58 On August 06, 2026, Guardant Health Inc (GH) shares fell 3.4% today, trading at $157.58. Over the past 52 weeks, the stock has ranged from a low of $43.66 to a
- 2026-08-01 GE Aerospace, AI Play Lead Five Stocks Near Buy Points Three of these watchlist stocks have already passed their earnings tests.
- 2026-07-31 AngloGold Ashanti Q2 30 June 2026 Earnings Release and Dividend Declaration AngloGold Ashanti plc (âAngloGold Ashantiâ, âAGAâ, the âCompanyâ or the âGroupâ) said Q2 2026 free cash flow* rose 36% year-on-year to $727m, fu